Back

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phaseⅠtrial

28 August 2026 (10:45 - 10:55)
Organised by: Logo
Congress Presentation Part of: New insights into lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Shilong Zhong

Guangdong Provincial People's Hospital, Guangzhou (China)

5 More presentations in this session

Presentation thumbnail
Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
Doctor D. Bhatt (New York City, US)
Abstract Slides
Presentation thumbnail
Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials
Doctor E. Stroes (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
Doctor G. De Ferrari (Turin, IT)
Abstract Slides
Presentation thumbnail
Intra-coronary imaging before and after PCSK9 inhibition stratified by residual inflammatory risk: a serial imaging sub-study of YELLOW III
Doctor P. C Revaiah (New York, US)
Abstract Slides
Presentation thumbnail
ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia
Professor S. Tsimikas (La Jolla, US)
Abstract Slides

Access the full session

Session thumbnail
New insights into lipid-lowering pharmacotherapy
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 10:45 CET
You may be interested in
thumbnail
Congress Presentation
Effect and safety of PCSK9 inhibitor in-hospital use on blood lipid level in the ACS patients: a systematic review and meta-analysis
13 April 2024
thumbnail
Congress Presentation
Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107
28 August 2022
thumbnail
Congress Presentation
SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study
1 September 2024
thumbnail
Congress Presentation
Inter-individual variability in LDL-C reductions with inclisiran - Data from ORION-10 and ORION-11
1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources